Evidence map›Paper›PMID 41051252›Full record

ReviewRheumatology (Oxford, England)2026

Understanding the burden of ANCA-associated vasculitis.

Bernhard Hellmich

Abstract readReview
In one paragraph

Review in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bernhard HellmichKlinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius KLINIKEN Kirchheim-Teck & Nürtingen, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany.ORCID 0000-0002-8014-1801

Funding

AstraZenecaVifor Fresenius Medical Care Renal Pharma AG
6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of frequently relapsing systemic autoimmune disorders characterized by vasculitis-related organ damage and multiple comorbidities related to chronic inflammation. Advances in immunosuppression-based therapies for AAV have considerably improved remission rates, reduced the risk of relapse, and improved survival in patients with AAV. However, mortality remains high compared with the general population and the benefits of treatment are often offset by treatment-related comorbidities, organ damage and adverse effects, particularly infections. The aim of this review is to investigate the key contributors to disease burden in patients with AAV and to describe strategies for improving health-related quality of life.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCost of IllnessComorbidityHumansImmunosuppressive AgentsQuality of LifeImmunosuppressive AgentsAAVANCA-associated vasculitisAnti-neutrophil cytoplasmic antibodyavacopandisease burdenglucocorticoidshealth-related quality of lifeimmunosuppression

Identifiers

PMID41051252
PMCPMC12783593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.